Get started Log in

ALPHA — Pharnext SCA Share News

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Brief: Pharnext Announces Appointments Of Susanne Dorn As Chief Regulatory Officer And Serge Fitoussi As Chief Medical Officer
14/01/2019 16:47
Brief: Pharnext Announces 2018 Half-Year Results
25/10/2018 06:36
Brief: Pharnext Announces Positive Topline Results From Pivotal Phase 3 Trial Of PXT3003
16/10/2018 06:41
Brief: Pharnext And Vitaccess Launch CMT&Me Observational Study
09/10/2018 06:47
Brief: Pharnext Announces Issuance Of New Composition Of Matter Patents For PLEODRUG PXT3003 And PXT864
18/07/2018 06:34
Brief: Pharnext Says EMA Agrees With Its Pediatric Investigation Plan For PXT3003
10/07/2018 06:34
Brief: Pharnext To Announce Results From Phase 3 Trial Of Pxt3003 By October 2018
22/06/2018 06:59
Brief: Pharnext Announces PXT3003 Was Granted Priority Review By The China Food And Drug Administration
14/06/2018 06:36
Brief: Pharnext Announces 20.5 Million Euro Bond Issue
13/06/2018 17:29
Brief: Pharnext Reports FY Operating Revenues EUR 3.3 mln vs EUR 4.4 mln Last Year
12/04/2018 23:04
Brief: Pharnext Successfully Raises 16 Million Euros Via Private Placement
11/04/2018 16:58
Brief: Pharnext: Successful Intermediate Analyses For Pleo-Cmt Phase III Clinical Trial
29/11/2017 17:30
Brief: Pharnext H1 net loss up at 10.1 million euros
19/10/2017 18:31
Brief: Pharnext amends protocol of international pivotal phase 3 trials of PXT3003
18/09/2017 17:01
Brief: Pharnext announces DSMB recommends continuing the ongoing Phase 3 trial of PXT3003
06/09/2017 16:46
Brief: Pharnext announces strategic partnership with Tasly
10/05/2017 05:47
Brief: China's Tasly Pharma, France's Pharnext plan JV in China
09/05/2017 12:30
Brief: Pharnext FY operating loss widens to 13.4 million euros
26/04/2017 17:02
Brief: Pharnext announces positive preclinical data for its PLEODRUG PXT864
29/03/2017 07:01
Brief: Pharnext announces Phase 3 of PXT3003 for treatment of CMT1A
16/03/2017 16:46